Ho, Alan Loh

Publications

Sort by

Co-Author Network

selected publications

Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 Academic Article GET IT
Times cited: 38
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 172
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. The Journal of clinical endocrinology and metabolism. 2019 Academic Article GET IT
Times cited: 168
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 149
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer research. 2018 Academic Article GET IT
Times cited: 61
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 101
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017 Academic Article GET IT
Times cited: 57
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 12
Androgen Receptor Signaling in Salivary Gland Cancer. Cancers. 2017 Information Resource GET IT
Times cited: 64
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA oncology. 2017 Academic Article GET IT
Times cited: 182
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 103
Unmet needs for patients with salivary gland cancer. Oral oncology. 2016 Editorial Article GET IT
Times cited: 5
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 151
Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Seminars in nuclear medicine. 2016 Information Resource GET IT
Times cited: 29
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 44
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 20
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer. 2014 Information Resource GET IT
Times cited: 101
Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Human pathology. 2014 Academic Article GET IT
Times cited: 106
Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. Journal of skin cancer. 2014 Academic Article GET IT
Times cited: 47
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 4
Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. Radiology and oncology. 2014 Academic Article GET IT
Times cited: 26
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. International journal of radiation oncology, biology, physics. 2013 Academic Article GET IT
Times cited: 47
Moving toward a better understanding of radioiodine action. Endocrine. 2013 Editorial Article GET IT
Times cited: 2
Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. Journal of radiation oncology. 2013 Academic Article GET IT
Times cited: 4
PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor. Anticancer research. 2013 Academic Article GET IT
Times cited: 22
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 176
Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 66
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 651
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013 Academic Article GET IT
Times cited: 40
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investigational new drugs. 2013 Information Resource GET IT
Times cited: 45
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PloS one. 2012 Academic Article GET IT
Times cited: 63
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer research. 2012 Academic Article GET IT
Times cited: 55
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer chemotherapy and pharmacology. 2012 Academic Article GET IT
Times cited: 27
The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell cycle (Georgetown, Tex.). 2012 Academic Article GET IT
Times cited: 48
Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011 Academic Article GET IT
Times cited: 62
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. International journal of radiation oncology, biology, physics. 2011 Academic Article GET IT
Times cited: 62
Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. Clinical advances in hematology & oncology : H&O. 2011 Information Resource GET IT
Times cited: 9
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. The Lancet. Oncology. 2010 Information Resource GET IT
Times cited: 204
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature genetics. 2010 Academic Article GET IT
Times cited: 611
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Molecular biology of the cell. 2009 Academic Article GET IT
Times cited: 85
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Molecular pharmacology. 2008 Academic Article GET IT
Times cited: 43
Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Molecular and cellular biology. 2006 Academic Article GET IT
Times cited: 164
Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 77
Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Current opinion in genetics & development. 2002 Information Resource GET IT
Times cited: 150
Mammary epithelial cell-cycle progression via the alpha(2)beta(1) integrin: unique and synergistic roles of the alpha(2) cytoplasmic domain. The American journal of pathology. 2001 Academic Article GET IT
Times cited: 37
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Molecular and cellular biology. 2001 Academic Article GET IT
Times cited: 181
Biological methods for cell-cycle synchronization of mammalian cells. BioTechniques. 2001 Information Resource GET IT
Times cited: 134
Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer research. 2001 Academic Article GET IT
Times cited: 356
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 2115

more ...

less ...

Background

education and training

M.D., Ph.D., Washington University School of Medicine 2003
B.S., Stanford University 1995

Contact

full name

Alan Loh Ho

VIVO Weill Cornell Medical College

Alan Loh Ho Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name